期刊
JOURNAL OF INFECTION AND CHEMOTHERAPY
卷 29, 期 4, 页码 391-400出版社
ELSEVIER
DOI: 10.1016/j.jiac.2023.01.010
关键词
Vancomycin; Dosing regimen; Hematologic malignancies; Augmented renal clearance; Neutropenia; Population pharmacokinetic model
The aim of this study was to develop a population pharmacokinetic (PK) model for vancomycin (VCM) in hematologic malignancies and propose an optimal dosing regimen. The results showed significant differences in VCM metabolism and clearance between patients with acute myeloid leukemia (AML) and those with neutropenia. Therefore, individualized dosing adjustment and therapeutic drug monitoring are recommended for AML patients.
Aim: Data on the pharmacokinetics (PK) and area under the curve (AUC)-based dosing strategy of vancomycin (VCM) in hematologic malignancies are limited. According to our preliminary narrative review, only a few population PK analyses in hematologic malignancies have been performed. Therefore, we aimed to develop a population PK model, investigate the factors influencing VCM PK, and propose an optimal dosing regimen for hematologic malignancies. Methods: A retrospective study was conducted in patients with underlying hematologic malignancies treated with VCM. A total of 148 patients were enrolled for population PK modeling. Simulation analyses were performed to identify dosing regimens achieving a target exposure of AUC0-24 of 400-600 mg h/L at the steady-state. Results: The VCM PK data were best described with a one-compartment model. Significant covariates included creatinine clearance (Ccr), diagnosis of acute myeloid leukemia (AML) and neutropenia on VCM clearance (CL), and body weight (WT) on the volume of distribution (Vd). The typical values of CL and Vd were 3.09 L/h (normalized to Ccr value of 90 mL/min) and 122 L/70 kg, respectively. Concerning the effect on VCM dosing, AML patients required 15% higher doses than non-AML patients, independently of renal function. In contrast, for neutropenic patients, only those with augmented renal clearance (ARC, Ccr value >= 130 mL/min) required a 10% dose increase compared to non-neutropenic patients. Conclusion: AML patients with neutropenia and ARC represent a critical population with a higher risk of VCM underexposure. Thus, individualized dosing adjustment and therapeutic drug monitoring are strongly recommended.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据